Development of Clay Nanoparticles in Pharmaceutical Industry

Year 2021, Volume: Volume 1 Issue: Issue 2, 54 - 57, 30.12.2021

Shahriyar Karımdoust Ekrem Kalkan Yalcin Kemal Bayhan Yousef Vasıgh Beheshteh X Beheshteh Gharıbı

Abstract

Nanotechnology has grown significantly in the medical field in recent years. This new technology, with the synthesis and introduction of a new drug system, has made a huge difference in the discussion of treatment and health. The preparation and production of drugs based on natural and mineral compounds and the drug delivery system to specific organs of the body is an example of this technology in the field of pharmacy. Mineral drugs, unlike chemical drugs, have no negative effects on various organs of the body. Nano-clays -with their unique properties -are an example of mineral drugs that play a very important role in the pharmaceutical industry today. Bentonite is a clay mineral that is mainly composed of smectite minerals. Ionic substitution, ductility, high cation exchange are important properties of smectite minerals. Due to the weak bond between the layers in this group, it is easy to add different molecules andpolymers between their layers, and for this reason, the clay minerals of the smectite group are very important in the pharmaceutical industry. Scientists are conducting research to purify, modify and optimize bentonite minerals and obtain mineral drugs compatible with the body's biological system.

Keywords

Nanotechnology, Nano-clays, Pharmaceutical Industry, Bentonite

References

• 1. Carretero, M.I. Clay minerals and their beneficial effects upon human health. A review. Applied Clay Science2002, 21, 155–163, doi:10.1016/S0169-1317(01)00085-0.
• 2. Choy, J.; Choi, S.; Oh, J.; Park, T. Clay minerals and layered double hydroxides for novel biological applications. Applied Clay Science2007, 36, 122–132, doi:10.1016/j.clay.2006.07.007.
• 3. Kim, M.H.; Choi, G.; Elzatahry, A.; Vinu, A.; Choy, Y. Bin; Choy, J.-H. Review of Clay-drug Hybrid Materials for Biomedical Applications: Administration Routes. Clays and Clay Minerals2016, 64, 115–130, doi:10.1346/CCMN.2016.0640204.
• 4. Bergaya, F.; Lagaly, G. Chapter 1 General Introduction: Clays, Clay Minerals, and Clay Science 2006, 1–18.
• 5. Carretero, M.I.; Pozo, M. Clay and non-clay minerals in the pharmaceutical industry. Applied Clay Science2009, 46, 73–80, doi:10.1016/j.clay.2009.07.017.
• 6. López-Galindo, A.; Viseras, C.; Aguzzi, C.; Cerezo, P. Pharmaceutical and Cosmetic Uses of Fibrous Clays 2011, 299–324.
• 7. Carretero, M.I.; Gomes, C.S.F.; Tateo, F. Clays, Drugs, and Human Health 2013, 711–764.
• 8. Khurana, I.S.; Kaur, S.; Kaur, H.; Khurana, R.K. Multifaceted role of clay minerals in pharmaceuticals. Future Science OA2015, 1, FSO6, doi:10.4155/fso.15.6.
• 9. Massaro, M.; Colletti, C.; Lazzara, G.; Riela, S. The Use of Some Clay Minerals as Natural Resources for Drug Carrier Applications. Journal of Functional Biomaterials2018, 9, 58, doi:10.3390/jfb9040058.
• 10. Mousavi, S.M.; Hashemi, S.A.; Salahi, S.; Hosseini, M.; Amani,A.M.; Babapoor, A. Development of Clay Nanoparticles Toward Bio and Medical Applications. Current Topics in the Utilization of Clay in Industrial and Medical Applications2018, 167–191.11. Theng, K.G. The Chemistry of Clay-Organic Reactions. Adam HilgerLtd., Rank Precision Ind., 29 King Street, London, WC2E 8JH; 1974; ISBN 0852742118 9780852742112.
• 12. Nemecz, E. Clay Minerals. Budapest, Hungary: Akademiai Kiado; 1981;
• 13. Chung, H.-E.; Kim, I.-S.; Baek, M.; Yu, J.; Choi, S.-J. Long-term cytotoxicity potential of anionic nanoclays in human cells. Toxicology and Environmental Health Sciences2011, 3, 129–133, doi:10.1007/s13530-011-0088-z.
• 14. Sánchez, C.J.; Parras, J.; Carretero, M.I. The effect of maturation upon the mineralogical and physicochemicalproperties of illitic-smectitic clays for pelotherapy. Clay Minerals2002, 37, 457–463, doi:10.1180/0009855023730045.
• 15. Veniale, F.; Barberis, E.; Carcangiu, G.; Morandi, N.; Setti, M.; Tamanini, M.; Tessier, D. Formulation of muds for pelotherapy: effects of “maturation” by different mineral waters. Applied Clay Science2004, 25, 135–148, doi:10.1016/j.clay.2003.10.002.
• 16. Gorchakov, V.N.; Dragun, G.N.; Kolmogorov, Y.P.; Smelova, V.A.; Tikhonova, L.I.; Tysjachnova, Y. V The using of SR XRF for estimation of macro-and microelement contents of biological objects at the clay treatment. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment2001, 470, 437–440, doi:10.1016/S0168-9002(01)01092-0.
• 17. Carretero, M.I.; Gomes, C.; Tateo, F. Clays and Human Health. In: Bergaya, F, Theng, B.K.G., Lagaly, G. (eds.), Handbook of Clay Science. Elsevier (The Netherlands); 2006;
• 18. Murray, H.H. Applied Clay Mineralogy; Occurrences, Processingand Application of Kaolins, Bentonites, Palygorskite, Sepiolite, and Common Clays. Elsevier, Amsterdam, The Netherlands; 2007;
• 19. Karimdoust, S.; Kalkan, E.; Vasigh, Y.; Gharibi, B. Synthesis of Nano-clays-based Drugs, Progression of the Pharmaceutical Industry. , Atatürk University, Nanoscience and Nanoengineering Application and Research Center, 24-26 November 2021, Erzurum, Turkey. In Proceedings of the World Congress on Applied Nanotechnology (W-CAN); 2021.
• 20. Savjani, K.T.; Gajjar, A.K.; Savjani, J.K. Drug Solubility: Importance and Enhancement Techniques. ISRN Pharmaceutics2012, 2012, 1–10, doi:10.5402/2012/195727.
• 21. Karimdoust, S.; Kalkan, E.; Vasigh, Y.; Ziba, Y.N. The Effect of Nano-clay on Human Gastrointestinal Health. Atatürk University,Nanoscience and Nanoengineering Application and Research Center, 24-26 November 2021, Erzurum, Turkey. In Proceedings of the World Congress on Applied Nanotechnology (W-CAN); 2021.
• 22. Kaur, M.; Datta, M. Diclofenac Sodium Adsorption onto Montmorillonite: Adsorption Equilibrium Studies and Drug Release Kinetics. Adsorption Science & Technology2014, 32, 365–387, doi:10.1260/0263-6174.32.5.365.
• 23. Floody, M.C.; Theng, B.K.G.; Reyes, P.; Mora, M.L. Natural nanoclays: applications and future trends –a Chilean perspective. Clay Minerals2009, 44, 161–176, doi:10.1180/claymin.2009.044.2.161.
• 24. Kryuchkova, M.; Danilushkina, A.; Lvov, Y.; Fakhrullin, R. Evaluation of toxicity of nanoclays and graphene oxide in vivo: a Paramecium caudatum study. Environmental Science: Nano2016, 3, 442–452, doi:10.1039/C5EN00201J.
• 25. Lazzara, G.; Riela, S.; Fakhrullin, R.F. Clay-based drug-delivery systems: what does the future hold? Therapeutic Delivery2017, 8, 633–646, doi:10.4155/tde-2017-0041.
• 26. Piétrement, O.; Castro-Smirnov, F.A.; Cam, E. Le; Aranda, P.; Ruiz-Hitzky, E.; Lopez, B.S. Sepiolite as a New Nanocarrier for DNA Transfer into Mammalian Cells: Proof of Concept, Issues and Perspectives. The Chemical Record2018, 18, 849–857, doi:10.1002/tcr.201700078.
• 27. Yilmaz, B.; Irmak, E.T.; Turhan, Y.; Doğan, S.; Doğan, M.; Turhan, O. Synthesis, Characterization and Biological Properties of Intercalated Kaolinite Nanoclays: Intercalation and Biocompatibility. Advances in Materials Science2019, 19, 83–99, doi:10.2478/adms-2019-0007.
• 28. Peixoto, D.; Pereira, I.; Pereira-Silva, M.; Veiga, F.; Hamblin, M.R.; Lvov, Y.; Liu, M.; Paiva-Santos, A.C. Emerging role of nanoclays in cancer research, diagnosis, and therapy. Coordination Chemistry Reviews2021, 440, 213956, doi:10.1016/j.ccr.2021.213956.
• 29. Lepoittevin, B.; Devalckenaere, M.; Pantoustier, N.; Alexandre, M.; Kubies, D.; Calberg, C.; Jérôme, R.; Dubois, P. Poly(ε-caprolactone)/clay nanocomposites prepared by melt intercalation: mechanical, thermal and rheological properties. Polymer2002, 43, 4017–4023, doi:10.1016/S0032-3861(02)00229-X.
• 30. Jeon, H.S.; Rameshwaram, J.K.; Kim, G.; Weinkauf, D.H. Characterizationof polyisoprene–clay nanocomposites prepared by solution blending. Polymer2003, 44, 5749–5758, doi:10.1016/S0032-3861(03)00466-X.
• 31. Wang, K.; Wang, C.; Li, J.; Su, J.; Zhang, Q.; Du, R.; Fu, Q. Effects of clay on phase morphology and mechanical properties in polyamide 6/EPDM-g-MA/organoclay ternary nanocomposites. Polymer2007, 48, 2144–2154, doi:10.1016/j.polymer.2007.01.070.
• 32. Guggenheim, S.; Adams, J.M.; Bain, D.C.; Bergaya, F.; Brigatti, M.F.; Drits, V.A.; Formoso, M.L.L.; Galán, E.; Kogure, T.;Stanjek, H. Summary of recommendations of nomenclature committees relevant to clay mineralogy: report of the Association Internationale pour l’Etude des Argiles (AIPEA) Nomenclature Committee for 2006. Clay Minerals2006, 41, 863–877, doi:10.1180/0009855064140225.
• 33. Bh, S.; M, P.; Vm, B.; Tp, H. Modified nano-clay formulation and their application. ~ 705 ~ International Journal of Chemical Studies2018, 6, 705–710.
• 34. Lu, T.; Gou, H.; Rao, H.; Zhao, G. Recent progress in nanoclay-based Pickering emulsion and applications. Journal of Environmental Chemical Engineering2021, 9, 105941, doi:10.1016/j.jece.2021.105941.
• 35. Zhang, D.; Zhou, C.-H.; Lin, C.-X.; Tong, D.-S.; Yu, W.-H. Synthesis of clay minerals. Applied Clay Science2010, 50, 1–11, doi:10.1016/j.clay.2010.06.019.
• 36. Gaskell, E.E.; Hamilton, A.R. Antimicrobial clay-based materials for wound care. Future Medicinal Chemistry2014, 6, 641–655, doi:10.4155/fmc.14.17.
• 37. Viseras, C.; Carazo, E.; Borrego-Sánchez, A.; García-Villén, F.; Sánchez-Espejo, R.; Cerezo, P.; Aguzzi, C. Clay Minerals in Skin Drug Delivery. Clays and Clay Minerals2019, 67, 59–71, doi:10.1007/s42860-018-0003-7.
• 38. Eisenhour, D.D.; Brown, R.K. Bentonite and Its Impact on Modern Life. Elements2009, 5, 83–88, doi:10.2113/gselements.5.2.83.
• 39. Khediri, F.; Mrad, A.I.; Azzouz, M.; Doughi, H.; Najjar, T.; Mathiex-Fortunet, H.; Garnier, P.; Cortot, A. Efficacy of Diosmectite (Smecta) ® in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study. Gastroenterology Research and Practice2011, 2011, 1–8, doi:10.1155/2011/783196.
• 40. Baek, M.; Choy, J.-H.; Choi, S.-J. Montmorillonite intercalated with glutathione for antioxidant delivery: Synthesis, characterization, and bioavailability evaluation. International Journal of Pharmaceutics2012, 425, 29–34, doi:10.1016/j.ijpharm.2012.01.015.